With the new licence, generic manufacturers and other companies based anywhere in the world can develop, manufacture and sell low cost, paediatric versions of raltegravir in countries where 98 percent of children with HIV in the developing world live
The Medicines Patent Pool (MPP) announces a collaboration with the University of Liverpool and a licence for the university’s Solid Drug Nanoparticle (SDN) technology to accelerate the development of WHO-recommended antiretrovirals as nanomedicines
The MPP publishes its July 2016 newsletter featuring an update on its last six months of progress.
Agenda item 15.1 – WHO Global Health Sector Strategies for HIV and Viral Hepatitis
MPP representative: Greg Perry